Yassa, R.; Lal, S. (1986). “Respiratory irregularity and tardive dyskinesia a prevalence study”. Acta Psychiatrica Scandinavica73 (5): 506–10. doi:10.1111/j.1600-0447.1986.tb02717.x. PMID2875609.
Yassa, Ramzy; Jones, Barry D. (1985). “Complications of tardive dyskinesia: A review”. Psychosomatics26 (4): 305–7, 310, 312–3. doi:10.1016/S0033-3182(85)72863-0. PMID2859630.
Dean, C. E.; Thuras, P. D. (2009). “Mortality and tardive dyskinesia: Long-term study using the US National Death Index”. The British Journal of Psychiatry194 (4): 360–4. doi:10.1192/bjp.bp.108.049395. PMID19336789.
Alexander, C; Power, P (2008). “A case of aripiprazole and tardive dyskinesia”. Journal of Psychopharmacology23 (2): 214–5. doi:10.1177/0269881108089591. PMID18515468.
Alexander, J (Mar 2013). “Aripiprazole induced tardive dyskinesia-accruing evidence”. Aust N Z J Psychiatry47 (3): 289-90. doi:10.1177/0004867412461058. PMID22990431.
Bergman H, Rathbone J, Agarwal V, Soares-Weiser K (February 2018). “Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia”. Cochrane Database Syst Re: CD000459. doi:10.1002/14651858.CD000459.pub3. PMID29409162.
Soares-Weiser K, Rathbone J, Ogawa Y, Shinohara K, Bergman H (March 2018). “Miscellaneous treatments for antipsychotic-induced tardive dyskinesia”. Cochrane Database Syst Re: CD000208. doi:10.1002/14651858.CD000208.pub2. PMID29552749.
Bergman H, Soares-Weiser K (January 2018). “Anticholinergic medication for antipsychotic-induced tardive dyskinesia”. Cochrane Database Syst Re: CD000204. doi:10.1002/14651858.CD000204.pub2. PMID29341071.
Soares-Weiser K, Maayan N, Bergman H (January 2018). “Vitamin E for antipsychotic-induced tardive dyskinesia”. Cochrane Database Syst Re: CD000209. doi:10.1002/14651858.CD000209.pub3. PMID29341067.
Alabed S, Latifeh Y, Mohammad HA, Bergman H (April 2018). “Gamma-aminobutyric acid agonists for antipsychotic-induced tardive dyskinesia”. Cochrane Database Syst Re: CD000203. doi:10.1002/14651858.CD000203.pub4. PMID29663328.
Rauchverger, B; Isakov, V; Jabarin, M (2007). “Olanzapine-induced tardive dystonia successfully treated by tetrabenazine”. The Journal of neuropsychiatry and clinical neurosciences19 (4): 484–5. doi:10.1176/appi.neuropsych.19.4.484-a. PMID18070868.
Bergman H, Bhoopathi PS, Soares-Weiser K (January 2018). “Benzodiazepines for antipsychotic-induced tardive dyskinesia”. Cochrane Database Syst Re: CD000205. doi:10.1002/14651858.CD000205.pub3. PMID29352477.
Richardson, Mary Ann; Bevans, Margaret L.; Read, Laura L.; Chao, Helen M.; Clelland, James D.; Suckow, Raymond F.; Maher, Timothy J.; Citrome, Leslie (2003). “Efficacy of the Branched-Chain Amino Acids in the Treatment of Tardive Dyskinesia in Men”. American Journal of Psychiatry160 (6): 1117–24. doi:10.1176/appi.ajp.160.6.1117. PMID12777270.
Llorca, Pierre-Michel; Chereau, Isabelle; Bayle, Frank-Jean; Lancon, Christophe (2002). “Tardive dyskinesias and antipsychotics: A review”. European Psychiatry17 (3): 129–38. doi:10.1016/S0924-9338(02)00647-8. PMID12052573.
Jeste, Dilip V.; Caligiuri, Michael P.; Paulsen, Jane S.; Heaton, Robert K.; Lacro, Jonathan P.; Harris, M. Jackuelyn; Bailey, Anne; Fell, Robert L. et al. (1995). “Risk of Tardive Dyskinesia in Older Patients: A Prospective Longitudinal Study of 266 Outpatients”. Archives of General Psychiatry52 (9): 756–65. doi:10.1001/archpsyc.1995.03950210050010. PMID7654127.
Tarsy, Daniel; Lungu, Codrin; Baldessarini, Ross J. (2011). “Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs”. In Vinken, P. J.; Bruyn, G. W.. Handbook of Clinical Neurology. Hyperkinetic Movement Disorders. 100. pp. 601–16. doi:10.1016/B978-0-444-52014-2.00043-4. ISBN978-0-444-52014-2. PMID21496610
Yassa, R.; Lal, S. (1986). “Respiratory irregularity and tardive dyskinesia a prevalence study”. Acta Psychiatrica Scandinavica73 (5): 506–10. doi:10.1111/j.1600-0447.1986.tb02717.x. PMID2875609.
Yassa, Ramzy; Jones, Barry D. (1985). “Complications of tardive dyskinesia: A review”. Psychosomatics26 (4): 305–7, 310, 312–3. doi:10.1016/S0033-3182(85)72863-0. PMID2859630.
Dean, C. E.; Thuras, P. D. (2009). “Mortality and tardive dyskinesia: Long-term study using the US National Death Index”. The British Journal of Psychiatry194 (4): 360–4. doi:10.1192/bjp.bp.108.049395. PMID19336789.
Baldessarini, Ross J. (1988). “A summary of current knowledge of tardive dyskinesia”. L'Encéphale14 (Spec Issue): 263–8. PMID2905654.
Alexander, C; Power, P (2008). “A case of aripiprazole and tardive dyskinesia”. Journal of Psychopharmacology23 (2): 214–5. doi:10.1177/0269881108089591. PMID18515468.
Alexander, J (Mar 2013). “Aripiprazole induced tardive dyskinesia-accruing evidence”. Aust N Z J Psychiatry47 (3): 289-90. doi:10.1177/0004867412461058. PMID22990431.
Crane, GE (1973). “Is tardive dyskinesia a drug effect?”. The American journal of psychiatry130 (9): 1043–4. PMID4727768.
Crane, GE (1973). “Rapid reversal of tardive dyskinesia”. The American journal of psychiatry130 (10): 1159. PMID4728916.
Bergman H, Rathbone J, Agarwal V, Soares-Weiser K (February 2018). “Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia”. Cochrane Database Syst Re: CD000459. doi:10.1002/14651858.CD000459.pub3. PMID29409162.
Soares-Weiser K, Rathbone J, Ogawa Y, Shinohara K, Bergman H (March 2018). “Miscellaneous treatments for antipsychotic-induced tardive dyskinesia”. Cochrane Database Syst Re: CD000208. doi:10.1002/14651858.CD000208.pub2. PMID29552749.
Bergman H, Soares-Weiser K (January 2018). “Anticholinergic medication for antipsychotic-induced tardive dyskinesia”. Cochrane Database Syst Re: CD000204. doi:10.1002/14651858.CD000204.pub2. PMID29341071.
Soares-Weiser K, Maayan N, Bergman H (January 2018). “Vitamin E for antipsychotic-induced tardive dyskinesia”. Cochrane Database Syst Re: CD000209. doi:10.1002/14651858.CD000209.pub3. PMID29341067.
Alabed S, Latifeh Y, Mohammad HA, Bergman H (April 2018). “Gamma-aminobutyric acid agonists for antipsychotic-induced tardive dyskinesia”. Cochrane Database Syst Re: CD000203. doi:10.1002/14651858.CD000203.pub4. PMID29663328.
Rauchverger, B; Isakov, V; Jabarin, M (2007). “Olanzapine-induced tardive dystonia successfully treated by tetrabenazine”. The Journal of neuropsychiatry and clinical neurosciences19 (4): 484–5. doi:10.1176/appi.neuropsych.19.4.484-a. PMID18070868.
Bergman H, Bhoopathi PS, Soares-Weiser K (January 2018). “Benzodiazepines for antipsychotic-induced tardive dyskinesia”. Cochrane Database Syst Re: CD000205. doi:10.1002/14651858.CD000205.pub3. PMID29352477.
Richardson, Mary Ann; Bevans, Margaret L.; Read, Laura L.; Chao, Helen M.; Clelland, James D.; Suckow, Raymond F.; Maher, Timothy J.; Citrome, Leslie (2003). “Efficacy of the Branched-Chain Amino Acids in the Treatment of Tardive Dyskinesia in Men”. American Journal of Psychiatry160 (6): 1117–24. doi:10.1176/appi.ajp.160.6.1117. PMID12777270.
Llorca, Pierre-Michel; Chereau, Isabelle; Bayle, Frank-Jean; Lancon, Christophe (2002). “Tardive dyskinesias and antipsychotics: A review”. European Psychiatry17 (3): 129–38. doi:10.1016/S0924-9338(02)00647-8. PMID12052573.
Glenmullen, Joseph (2001). Prozac Backlash: Overcoming the Dangers of Prozac, Zoloft, Paxil, and Other Antidepressants With Safe, Effective Alternatives. New York: Simon & Schuster. p. 38. ISBN978-0-7432-0062-2[信頼性の低い医学の情報源?] ::referring to Glazer, William M.; Morgenstern, Hal; Doucette, John T. (1993). “Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications”. Journal of Clinical Psychiatry54 (4): 133–9. PMID8098030.
Jeste, Dilip V.; Caligiuri, Michael P.; Paulsen, Jane S.; Heaton, Robert K.; Lacro, Jonathan P.; Harris, M. Jackuelyn; Bailey, Anne; Fell, Robert L. et al. (1995). “Risk of Tardive Dyskinesia in Older Patients: A Prospective Longitudinal Study of 266 Outpatients”. Archives of General Psychiatry52 (9): 756–65. doi:10.1001/archpsyc.1995.03950210050010. PMID7654127.
Marshall, DL; Hazlet, TK; Gardner, JS; Blough, DK (2002). “Neuroleptic drug exposure and incidence of tardive dyskinesia: A records-based case-control study”. Journal of managed care pharmacy8 (4): 259–65. PMID14613418.
Tarsy, Daniel; Lungu, Codrin; Baldessarini, Ross J. (2011). “Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs”. In Vinken, P. J.; Bruyn, G. W.. Handbook of Clinical Neurology. Hyperkinetic Movement Disorders. 100. pp. 601–16. doi:10.1016/B978-0-444-52014-2.00043-4. ISBN978-0-444-52014-2. PMID21496610
National Institutes of Health, National Institute of Neurological Disorders and Stroke. (2011). Ninds tardive dyskinesia information page. Retrieved from website: http://www.ninds.nih.gov/disorders/tardive/tardive.htm